About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. S ...

DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Erich Spangenberg has been appointed as the Chief Executive Officer of its health care IP-focused subsidiary, Spectral IP. "Spectral AI is fortunate that our largest shareholder, Erich Spangenberg, has agreed to assume the CEO role at Spectral IP. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to To Commission File No. 001-40058 SPECTRAL AI, INC. (Exact name of registrant as specified in its charter) Delaware 85-3987148 (State or other jurisdiction of in ...

Exhibit 99.1 Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results 2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024 Commercialization Underway with Revenue Expected in 2H 2024 for DeepView AI-Burn Indication in the UK On Track for Additional Regulatory Submissions in US and UK for DeepView System Burn and Diabetic Foot Ulcer Indications DALLAS, TX – March 27, 2024 - Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an art ...

财务数据和关键指标变化 - 第四季度研发收入为5.3亿美元,同比下降13.1% [30] - 全年研发收入为18.1亿美元,同比下降28.8% [34] - 第四季度毛利率为46.1%,同比上升5个百分点 [32] - 全年毛利率为43.6%,同比上升0.9个百分点 [35] - 第四季度一般及行政费用为5.4亿美元,同比增加25.6% [33] - 全年一般及行政费用为20.9亿美元,同比增加54.8% [36] - 全年研发费用为15.1亿美元,同比下降8.5% [37] 各条业务线数据和关键指标变化 - 公司目前主要专注于烧伤和糖尿病足溃疡两个临床适应症 [16][17] - 公司认为DeepView系统可以在未来支持多种临床适应症 [18] 各个市场数据和关键指标变化 - 2023年9月,公司获得了价值高达1.5亿美元的美国政府Project BioShield合同,这是公司有史以来最大的合同 [20] - 2024年1月,公司启动了一项验证性临床试验,用于获得DeepView系统用于烧伤的FDA批准 [21] - 2024年2月,公司获得了英国UKCA认证,可以在英国开始销售DeepView系统用于烧伤 [22] - 公司预计将于2024年下半年开始在英国产生商业收入 [22] - 公司计划于2025年在美国提交DeepView系统用于烧伤的监管申请,并于2026年在美国和英国获得用于糖尿病足溃疡的监管批准 [24] 公司战略和发展方向及行业竞争 - 公司的目标是让DeepView系统成为急诊室、医院、烧伤中心和诊所的临床治疗流程的一部分 [19] - 公司最近成立了一家全资子公司Spectral IP,专注于开发或收购适用于更广泛人工智能生态系统的知识产权 [25][26] 管理层对经营环境和未来前景的评论 - 公司CEO认为DeepView系统可以提供更有效和更高效的医疗保健,惠及患者、医生、机构和支付方 [10][11][12][13][14][15][16][17] - 公司CFO表示,公司最近的融资协议和多年期无需摊薄的政府合同资金,为实现战略目标提供了良好的财务基础 [39][40][41] - 公司预计2024年收入将达到28亿美元,较2023年增长约55% [41] 问答环节重要的提问和回答 问题1 **Ryan Zimmerman 提问** 询问公司在英国的进展情况,以及对未来的预期 [48][49][50] **Peter Carlson 回答** 公司已在英国部署了2台设备,并计划在未来几个月内部署5-6台设备。公司正在与这些诊所合作,收集实际使用数据,为后续商业化做准备 [49][50] 问题2 **Carl Byrnes 提问** 询问公司在英国的人员配置和设备部署情况,以及2024年收入指引是否包括英国销售 [62][63][64] **Peter Carlson 回答** 公司在英国的人员配置较少,主要包括制造、临床和销售人员。英国销售收入不会对2024年28亿美元的收入指引产生重大影响,属于额外收入 [64][65] 问题3 **John Vandermosten 提问** 询问公司与政府合同的结算方式和覆盖范围 [68][69][70][71] **Vincent Capone 回答** 公司每月向政府提交费用账单,并在次月内收到付款。政府合同覆盖临床试验的全部费用,包括间接费用 [69][70][71]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: SPECTRAL AI, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 85-3987148 (State or other jurisdiction of (I.R. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40058 ROSECLIFF ACQUISITION CORP I (Exact Name of Registrant as Specified in Its Charter) Delaware 85-3987148 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40058 ROSECLIFF ACQUISITION CORP I (Exact Name of Registrant as Specified in Its Charter) Delaware 85-3987148 (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to To Commission File No. 001-40058 ROSECLIFF ACQUISITION CORP I (Exact name of registrant as specified in its charter) Delaware 85-3987148 (State or other jurisdi ...